Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asciminib in Pediatric Participants With Ph+ CML-CP
NCT07354074Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Apr 2026
- Primary completion
- Feb 2033
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 15
01
Overview
A Phase 2 trial of asciminib in chronic myelogenous leukemia (CML), sponsored by Novartis. Started Apr 2026; status: recruiting.
02
Drugs
asciminib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT07354074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07354074.